PlocamiumAI develops artificial intelligence applications for oncology drug discovery and development. The entity appeared in coverage of AstraZeneca-Daiichi's triple-negative breast cancer therapeutic approval, suggesting involvement in computational biology or AI-driven biotech applications.
Full PSI intelligence, network analysis, EDGAR filings, and predicted links require an access token.
Notes, edits, or content requests — sent directly to James.